Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Except one, all studies showed suppressing effects for RSV on the production of AGEs or receptor for advanced glycation end products (RAGE) and its detrimental consequences including oxidative stress, inflammatory response, cellular immune reactions, insulin response, and atherosclerosis. 31185146 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE There is accumulating evidence that the AGEs-RAGE interaction plays an important role in accelerated atherosclerosis in diabetes. 31378770 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 GeneticVariation disease BEFREE Furthermore, compared with the corresponding wild-type genotype, the rs2269422 single-nucleotide polymorphism of RAGE was associated with the susceptibility of patients with CAD to atherosclerosis. 30783474 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Aging (chronic age-related diseases); ii. metabolic (hyperglycemia advanced glycation end products and its receptor (AGE/RAGE) interactions and hyperinsulinemia-insulin resistance (a linking linchpin); iii. oxidative stress (reactive oxygen-nitrogen species); iv. inflammation (peripheral macrophage and central brain microglia); v. vascular (macrovascular accelerated atherosclerosis-vascular stiffening and microvascular NVU/neuroglial remodeling) with resulting impaired cerebral blood flow. 31569571 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE RAGE does not seem to play a major role in the development of NASH or atherosclerosis in a hyperlipidemic mouse model. 30323247 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE These results demonstrated a potential role of monocyte adhesion, chemotaxis, and macrophage polarization in the development cardiovascular diseases induced by IH and identified that RAGE could be a promising therapeutic target to prevent atherosclerosis in patients with OSA. 30402462 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE These AGE molecules bind to their respective receptors called the receptor for advanced glycation end products (RAGE) and initiate several aberrant signaling pathways leading to onset of diseases such as diabetes, Alzheimer's, atherosclerosis, heart failure and cancer. 28546110 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Atorvastatin improves plaque stability in diabetic atherosclerosis through the RAGE pathway. 29509268 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Blockade of receptor for advanced glycation end products (RAGE) attenuates vascular oxidative stress and development of atherosclerosis. 28826719 2017
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 AlteredExpression disease BEFREE High mobility group box 1 (HMGB1) and receptor for advanced glycation end products (RAGE) cause the activation of intracellular signaling, gene expression, and production of inflammatory cytokines and have been linked to many inflammatory disease states such as diabetes mellitus and atherosclerosis. 28092162 2017
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Receptor for advanced glycation end products (RAGE), a member of cell adhesion molecules, plays an important role in chronic inflammation and atherosclerosis. 28535664 2017
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE This study, therefore, identifies SAA as a potential new uremic toxin involved in uremia-related atherosclerosis through interaction with RAGE. 26988587 2016
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE The receptor for advanced glycosylation end products (RAGE) has been widely linked to diabetic atherosclerosis, but its effects on coronary artery disease (CAD) and ischemic stroke (IS) remain controversial. 27930580 2016
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Multiligand receptor for advanced glycation end products (RAGE), osteoprotegerin, and Golgb1 genes may be implicated in atherosclerosis and vascular diseases. 26664786 2015
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE For example, soluble RAGE reduces murine atherosclerosis and vascular inflammation. 26515415 2015
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Advanced glycosylation end product-specific receptor (AGER) signaling has been implicated in atherosclerosis. 26226616 2015
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE We also outline novel treatments targeting the AGE-RAGE axis and specific Nox isoforms, which hold great promise in attenuating the development of diabetes-associated atherosclerosis and diabetic nephropathy. 26323666 2015
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Genetics of Plasma Soluble Receptor for Advanced Glycation End-Products and Cardiovascular Outcomes in a Community-based Population: Results from the Atherosclerosis Risk in Communities Study. 26083729 2015
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Receptor for advanced glycation end products (RAGE) is a cell-surface molecule member of the immunoglobulin superfamily and thought to play a critical role in diabetic atherosclerosis. 24078092 2013
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Therefore these results suggested that first, RAGE activation may be important in mediating AngII-induced atherogenesis, and second, AngII activation is a major pathway in the development of atherosclerosis. 23936343 2013
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Soluble receptor for advanced glycation end products RAGE (sRAGE), a secretory form of RAGE, plays an important role in suppressing RAGE signals that induce pro-inflammatory gene activation in a range of inflammatory diseases, such as Alzheimer's disease, complications of diabetes mellitus and atherosclerosis. 23708564 2013
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Receptor for advanced glycation end products (RAGE) and its multiple ligands have been implicated in the pathogenesis of accelerated atherosclerosis; however, little is known about the effects of RAGE activation on vascular calcification. 21512281 2011
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease BEFREE Proinflammatory cell activation via the receptor for advanced glycation end products (RAGE) pathway may play a central pathogenetic role in atherosclerosis. 21472666 2011
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease CTD_human Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation. 20372816 2010
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.600 Biomarker disease RGD High expression of AGE and RAGE in the livers and arteries of rats with NASH may contribute to the pathogenesis of NASH and early atherosclerosis. 20835270 2010